electroCore (NASDAQ:ECOR – Get Free Report) is anticipated to release its Q3 2026 results after the market closes on Wednesday, November 4th. Analysts expect electroCore to announce earnings of ($0.26) per share and revenue of $10.93 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Wednesday, November 4, 2026 at 4:30 PM ET.
electroCore (NASDAQ:ECOR – Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.33) EPS for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.09. The company had revenue of $9.45 million for the quarter, compared to analysts’ expectations of $9.49 million. On average, analysts expect electroCore to post ($1.40) EPS for the current fiscal year and ($0.68) EPS for the next fiscal year.
electroCore Price Performance
Shares of electroCore stock opened at $7.76 on Wednesday. The business’s fifty day moving average is $9.64 and its two-hundred day moving average is $7.70. electroCore has a fifty-two week low of $4.41 and a fifty-two week high of $12.70.
Insiders Place Their Bets
In related news, Director Thomas Errico acquired 5,000 shares of the firm’s stock in a transaction dated Monday, September 14th. The stock was acquired at an average cost of $9.82 per share, for a total transaction of $49,100.00. Following the completion of the acquisition, the director directly owned 363,904 shares of the company’s stock, valued at approximately $3,573,537.28. The trade was a 1.39% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Joshua S. Lev sold 3,000 shares of electroCore stock in a transaction dated Tuesday, August 25th. The stock was sold at an average price of $9.36, for a total value of $28,080.00. Following the transaction, the chief financial officer directly owned 84,889 shares in the company, valued at approximately $794,561.04. The trade was a 3.41% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 20,000 shares of company stock worth $200,120 over the last quarter. 7.80% of the stock is currently owned by company insiders.
Analyst Upgrades and Downgrades
Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of electroCore in a research note on Monday, September 21st. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $18.00.
View Our Latest Stock Analysis on electroCore
About electroCore
electroCore, Inc (NASDAQ: ECOR) is a commercial-stage medical device company focused on bioelectronic medicine and non-invasive vagus nerve stimulation (nVNS). Its technology is designed to stimulate the vagus nerve through the neck without requiring surgery or implanted components.
The company’s primary prescription product is gammaCore, a handheld nVNS device used for the acute treatment of pain associated with migraine and episodic cluster headaches in adults. electroCore also markets consumer-oriented products, including Truvaga, a handheld vagus nerve stimulation device positioned for general wellness applications.
Featured Stories
- Five stocks we like better than electroCore
- Hidden in Plain Sight: 2 Earnings Winners Investors May Have Missed
- These 3 New ETFs Are Turning Heads—Are They Worth Buying?
- Coca-Cola Stock Is Everything AI Isn’t—And That’s Its Biggest Strength
- Apple’s Foldable iPhone Sold Out in Minutes, But Wall Street Has Questions
Receive News & Ratings for electroCore Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for electroCore and related companies with MarketBeat.com's FREE daily email newsletter.
